Sign in
Taking people in United StatesNo phase

Tests virtual reality as added pain relief for children with sickle cell disease

Tests virtual reality alongside usual care for pain crises in children with sickle cell disease.

Key facts

Who runs it
Louisiana State University Health Sciences Center in New Orleans
Where
New Orleans, United StatesSee the site
Trial code
Registry title
Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain
Status
Recruiting
People taking part
36 people, planned
Started
12 Sept 2024
Planned end
19 Dec 2025
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • KindVR Aqua Program
Record updated
14 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people with sickle cell disease who are admitted to hospital with a vaso-occlusive pain crisis. It tests virtual reality added to standard pain care.

Age
8 to 21 years
Sex
All sexes can join.
Disease stage
A vaso-occlusive pain crisis that needs hospital admission for pain management.

Main reasons for not taking part

  • Sickle cell complications needing more than standard pain care, such as acute chest syndrome, splenic sequestration, post-operative pain or stroke
  • Known cognitive or neurological deficits
  • Not able to use the virtual reality equipment or answer questions appropriately
  • Already took part in this study
  • Study team cannot start the study treatment within the first 24 hours of admission

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Patient ≥ 8 up to 21 years of age
  • Presenting to CHNOLA ER or outside facility with chief complaint of vaso-occlusive pain crisis, requiring inpatient admission for further pain management
  • No known cognitive or neurological deficits
  • Parental/guardian permission (informed consent) and if appropriate, child assent

Who cannot take part

  • Patient has previously participated in the study
  • Patents upon admission found to have sequela of their sickle cell disease that would require medical therapy greater than the standard of care for a vaso-occlusive pain event. This includes acute chest syndrome, splenic sequestration, post-operative pain, and/or cerebrovascular accident
  • Failure to obtain or refusal to provide parental/guardian permission (informed consent) and if appropriate child assent
  • Patients aged 7-years-old and younger
  • Patients who are developmentally or cognitively incapable of using VR equipment and answering questions appropriately
  • Study team is unable to initiate study interventions within the first 24 hours of a patient's admission

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 8 and 21 years old?

Where in United States

  • Children's Hospital of New OrleansNew Orleans, United StatesContact: Molly E Sonenklar, MDTaking people

About the trial

What the trial wants to find out

The goal of this randomized control clinical trial is to learn if virtual reality can be used to treat sickle cell pain in children. The main questions it aims to answer are:

Read full original descriptionShow less

Does virtual reality reduce pain severity during a child's hospital stay for a vaso-occlusive pain crisis?

Does virtual reality decrease the daily use of opiates?

Researchers will compare standard therapy to the use of standard therapy plus a daily virtual reality experience to see if virtual reality works to treat sickle cell pain.

All patients will:

- Be asked to fill out a pain assessment survey three times daily for up to 3 days

If randomized to intervention arm, patients will:

* Participate in an immersive virtual reality experience once daily for up to 3 days * Fill out a survey twice daily to monitor for side effects from virtual reality experience * Fill out a satisfaction survey once during the study period

The 2 groups in the trial

  • ControlsNo study treatment, for comparison

    Control patients will continue to receive the standard of care for their vaso-occlusive pain (IV fluid hydration, scheduled IV NSAID, and opiate medication) and have repeat pain assessments at 1 hour and 4 hours from their baseline assessment. This same timeline will occur on days 2 and 3 of admission

  • CasesTreatment being tested

    In addition to receiving the standard of care for their vaso-occlusive pain, the case patients will have the opportunity to participate in the immersive VR experience after completing their initial pain assessment simulator sickness survey. Following the intervention, their pain levels will be reassessed at the 1-hour and 4-hour mark from their baseline assessment. Additionally, they will be asked to fill out an additional simulator sickness survey upon completion of the VR experience. This same timeline will occur on days 2 and 3 of admission. Prior to discharge or discontinuation from the study, the case patients will be asked to fill out the post-study questionnaire.

    Treatment: KindVR Aqua Program

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Changing the View of Pain: Using Virtual Reality As Adjunctive Therapy for Sickle Cell Pain in Pediatric Patients
Plain-language title
Tests virtual reality as added pain relief for children with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06773715, who can take part
Record updated
14 January 2025